Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

NARecruitingINTERVENTIONAL
Enrollment

152,000

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

September 30, 2025

Conditions
Venous Thromboembolic DiseasePulmonary Embolism and ThrombosisDeep Vein ThrombosisHospitalism
Interventions
OTHER

EHR (electronic health record) alert

Pop-up alert that informs the discharging clinician that the patient meets criteria to be considered for extended duration thromboprophylaxis

OTHER

No EHR (electronic health record) alert

During the baseline phase while risk is assessed and stored, no alerting occurs

Trial Locations (1)

84107

RECRUITING

Intermountain Medical Center, Murray

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Scott C. Woller, MD

OTHER

NCT06232551 - Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism | Biotech Hunter | Biotech Hunter